Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Wednesday 26 August →